Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 36 days later Jun 1, 2030 → Jul 7, 2030
See other at-risk trials from The Netherlands Cancer Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Primary and study completion dates: Jul 7, 2030 to Aug 2, 2030
    • Start date changed from estimate of Sep 7, 2026 to Oct 2, 2026
    • Eligibility criteria expanded, about 32 words
    • Site details revised
  2. Start date: Aug 1, 2026 to Sep 7, 2026
    • Primary and study completion pushed from Jun 1, 2030 to Jul 7, 2030
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC). The aim is to determine whether differences in tracer uptake can be detected between these groups, as translational studies indicate that HER2-mutated tumors may internalize trastuzumab-based agents more efficiently than tumors that solely overexpressed HER2.
Trial Details
NCT Number NCT07436858
Lead Sponsor The Netherlands Cancer Institute
Conditions
(from sponsor)		 Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov